Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Conflict of interest br Acknowledgements We
2021-07-21

Conflict of interest Acknowledgements We wish to thank Arantza Pérez (University of the Basque Country) for her technical contribution to this study. This work was supported by grants from the Jesús Gangoiti-Barrera Foundation, Gobierno Vasco (GIC07/84), MEC () and SAIOTEK (SA-2008/00046).
-
br RING dimerization RING type
2021-07-20

RING dimerization RING-type domains are found in many different structural contexts. While many exist as single-chain bcl2 (Fig. 3A), a notable feature of RING-type E3s is their tendency to form homodimers and heterodimers (Fig. 3C–F). Homodimeric RING-type E3s include cIAP, RNF4, BIRC7 (shown in
-
p kip is a member of the cyclin
2021-07-20

p27kip1 is a member of the cyclin-dependent kinase (CDK) inhibitor family that acts as a potent tumor suppressor in a variety of human cancers and negatively regulates the transition of cells from the G1 to S phase of the cell cycle, protects against inflammatory injury and promotes epithelial diffe
-
Compound A and Compound B Fig were
2021-07-20

Compound A and Compound B (Fig. 4) were found in our in vitro screening assays and have similar CRF1 receptor in vitro profiles (Table 1). When binding was investigated using [125I]-CRF in ex vivo assay, Compound A inhibited binding of [125I]-CRF both in the frontal cortex and the pituitary; howeve
-
Tubastatin A HCl receptor Survival analysis has been widely
2021-07-20

Survival analysis has been widely used in medical science, economics, finance, and social science, among others. In many studies, survival data have primary outcomes or responses that are subject to censoring. The Cox model [7], [8] is the most commonly used regression model for survival data, and t
-
Many studies have also demonstrated that CK
2021-07-20

Many studies have also demonstrated that CK2 inhibition profoundly affects the PI3K/AKT pathway in different cancer models; promising results have been obtained in hematological malignancies (Buontempo et al., 2014, Borgo et al., 2013, Piazza et al., 2012, Cheong et al., 2010, Gowda et al., 2016), a
-
Introduction br CK in the Regulation
2021-07-20

Introduction CK1 in the Regulation of Hh Pathway CK1 was initially identified as a negative regulator of Hh signaling at the level of transcription factor Ci by genetic studies in Drosophila and genome-wide RNAi screen in Drosophila cultured 5 03 australia (Jia et al., 2005, Lum et al., 2003, P
-
With regards to what might represent a typical baseline ChE
2021-07-20

With regards to what might represent a typical “baseline” ChE (or AChE) activity in Saccostrea sp., it SMER 3 australia should be remembered that the observed enzyme responses were obtained in laboratory exposures, over a narrow experimental window (96h), with specimens collected over the course of
-
An ideal CHK inhibitor would be minimally cytotoxic while
2021-07-20

An ideal CHK-1 inhibitor would be minimally cytotoxic, while enhancing the anti-tumor effect of a real cytotoxic agent that would be used in combination with the inhibitor. Our CHK-1 inhibitors have shown excellent selectivity over a panel of kinases including those regulating the cell cycle, but th
-
Enlarging the ligand binding pocket by
2021-07-19

Enlarging the ligand-binding pocket by reduction of the size of the residue F435 switched DES to an agonist indicating that F435 is involved in mediating the antagonistic effect of DES (Fig. 7E) [13]. The conformation of the smaller side chain of L435 was either not altered by DES or was too small t
-
The optimization of the lead compound
2021-07-19

The optimization of the lead compound () was initiated and the initial key SAR and the results of the structural modifications of lead compound are summarized in . Replacement of the carboxylic Triflusal mg moiety with other functional groups led to loss of functional activity against EP4 receptor
-
br Materials and methods br
2021-07-19

Materials and methods Results Discussion Inflammatory signalling and in particular the arachidonic dopamine hydrochloride synthesis cascade have been suggested as targets for disease modification, optimization of the therapeutic response, and even restoration of pharmacosensitivity (Potsch
-
br Activatable photoacoustic probes Photoacoustic PA
2021-07-19

Activatable photoacoustic probes Photoacoustic (PA) imaging is a recently developed technique [47]. The imaging approach uses probes that absorb a pulsed laser beam and convert light energy into acoustic signals. It combines the advantages of the high sensitivity offered by optical imaging and th
-
Our data demonstrate that MPO
2021-07-19

Our data demonstrate that MPO increased ETRB mRNA expression, which translated into an increase in ETRB protein expression, which proved to be dependent on the enzyme's catalytic activity. Of importance, addition of MPO was sufficient to increase ETRB expression, revealing that endogenous (endotheli
-
ELUXA HM EMSI is an ongoing pivotal Phase II global
2021-07-19

ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp
15877 records 610/1059 page Previous Next First page 上5页 606607608609610 下5页 Last page